Thank you for standing by and welcome to MaxCyte's Fourth Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. Operator instructions. As a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Erik Abdo, Investor Relations. Please go ahead.

Good afternoon, everyone. Thank you for participating in today's conference call. Joining me on the call for MaxCyte, we have Maher Masoud, President and Chief Executive Officer; and Doug Swirsky, Chief Financial Officer. Earlier today, MaxCyte released financial results for the fourth quarter and full year ended December 31, 2024. A copy of the press release is available on the company's website. Before we begin, I need to read the following statement. Statements or comments made during this call may be forward-looking statements within the meaning of federal securities laws. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements. Actual results may differ materially from those expressed or implied in any forward-looking statements due to a variety of factors, which are discussed in detail in our SEC filings. Except as required by applicable law, the company has no obligation to publicly update any forward-looking statements, whether because of new information, future events or otherwise. And with that, I'll turn the call over to Maher.

Thank you, Erik. Good afternoon, everyone, and thank you for joining MaxCyte's fourth quarter and full year 2024 earnings call. 2024 has been a strong year for MaxCyte. Highlighted by our return to core revenue growth, strategic improvements to our team and operations, and the support of CASGEVY launch, the first approved non-viral cell therapy with our premier electroporation platform. Throughout the year, our team has worked diligently to assess ways in which the company can continually improve. We evaluated and implemented new strategic initiatives and process improvements, which streamlined our organization by increasing capital and operational efficiency. We invested prudently within organic areas of the company that we believe promise the best return and will contribute to long-term growth while reducing spend in redundant or non-core areas. We also announced the acquisition of SeQure Dx early this year, which I am incredibly excited about and will touch upon in a moment. Overall, I believe that the thoughtful and strategic changes at MaxCyte throughout 2024 enabled us to grow core revenue in a difficult environment and position us well for 2025. Now we'll start by discussing our recent acquisition of SeQure Dx. When we look at the evolving cell and gene therapy field, safety is becoming increasingly paramount to therapy, which is exactly where SeQure Dx fits. SeQure Dx is a services platform that provides a safety assessment of cell and gene therapy development early in the discovery process. With SeQure Dx now integrated to MaxCyte, we can offer customers a comprehensive suite of assays that provide on and off target gene editing assessments that are applicable across a variety of viral and non-viral gene editing modalities. Our three assays; screening, nomination and confirmation are each utilized at different stages in development for both ex vivo and in vivo therapy, beginning in the discovery stage and through preclinical development and IND-enabling studies. Not only does off target editing profiling of programs improve the safety profile of therapies, but it also decreases time to clinic, unexpected costs and potential delays, ultimately increasing the likelihood of program success. We see significant opportunities with SeQure Dx in our portfolio, as MaxCyte can now support both ex vivo and in vivo cell and gene therapy developers. The acquisition has immediate cross-selling opportunities, with MaxCyte now able to work with customers earlier in discovery and able to offer SeQure Dx services to MaxCyte's existing customers as well. We are already seeing the benefits of adding SeQure Dx to our product portfolio and have had great success integrating their team into MaxCyte. We believe this acquisition is an important step forward in positioning MaxCyte to become a premier end-to-end cell and gene engineering platform, with the ability to provide a range of offerings and services throughout the entirety of development. Turning to our results, MaxCyte reported 38.6 million of total revenue for full year 2024, which included core business revenue of 32.5 million, at the high end of our pre-announced range provided in January. We were pleased with our team's commercial execution over the course of the year, through a stable but challenging environment. We grew our instrument installed base to 760 compared to an installed base of 683 at the end of 2023. Instrument revenue for the year was 7.1 million, which was impacted by a continuation of customer caution on capital expenditure. Though the operating environment remains challenging for our customers, we saw stability through 2024 and have seen some areas of improvement, including PA sales, which we reported very healthy revenue growth of 36% compared to 2023. As we head into 2025, we remain cautiously optimistic that the funding environment for our customers will improve in 2025. Overall, we continue to be impressed by the evolution of cell therapy towards new editing technology and new indications, and believe MaxCyte is extremely well positioned within the industry. Customers continue to see the value in MaxCyte's offering, leading to an expansion of our SPL portfolio at a record rate in 2024, with six new SPLs signed throughout the year. As of the end of 2024, we had a total of 28 active SPL customers, which includes 18 active clinical programs and one commercial program. Previously, we have discussed the total pre-commercial milestone potential across our SPL agreements as being greater than $2 billion. As this metric includes both existing SPL programs currently in clinical development and future SPL programs that are encompassed in our SPL agreements, we thought it would be very helpful to provide a new metric on the potential value creation from the existing active SPL programs currently in clinical development under our SPL agreements. Of the 18 active clinical programs under our SPL agreements, the total pre-commercial milestone potential is greater than 220 million, including about 10 million of milestone revenue that has already been received. These 18 programs have cleared IND or equivalent, and range from Phase 1 trials to programs entering pivotal trials this year. We see tremendous value potential for these programs over time. To further highlight the tremendous potential of our SPL portfolio, at the time of our IPO in late 2021, we were enabling 12 active clinical programs. And now with 18 active clinical programs, this represents a 50% growth in the number of active clinical programs we enabled, while the overall market for non-viral clinical programs has grown 25% during the same time period. We are continuing to strengthen our SPL portfolio. We recently signed our first SPL of 2025, TG Therapeutics in February, who entered into an agreement with Precision Biosciences to acquire a license to Azer-Cel. Following the addition of TG, we now have 29 active SPL customers. TG Therapeutics is a commercial biopharmaceutical company focused on novel treatments for B-cell diseases and is currently advancing towards a Phase 1 clinical trial for Azer-Cel and progressive forms of MS. Our SPL pipeline is very healthy as we enter 2025, and we believe we will continue to sign new SPLs at our historical rate of three to five new agreements this year. The opportunity in the cell and gene therapy industry continues to grow, which supports MaxCyte's opportunity to expand its SPL portfolio. We believe there are approximately 201 cell and gene therapy biotechnology companies as of the end of 2024, of which there exist approximately 83 non-viral cell and gene therapy biotechs that MaxCyte's potential to sign an SPL with. This SPL opportunity has grown over 50% since the time of our IPO and signifies a tremendous potential for non-viral cell therapies to help patients. We have capitalized on the growing SPL opportunity since the time of our IPO by more than doubling our SPL portfolio over this period. We finished the year with approximately 6.1 million in SPL program-related revenue, ahead of our initial guidance provided a year ago. Several programs supported by MaxCyte's platform progressed through the clinic in 2024 and achieved new milestones. A small amount of SPL program-related revenue in 2024 was from commercial royalty revenue related to CASGEVY following completion of patient doses. We remain excited about the opportunity of CASGEVY and strongly believe in its potential to benefit patients around the world. During Vertex's fourth quarter earnings call in February, the company reported that there are now approximately 50 patients who have completed cell collection, up from approximately 30 patients noted on their third quarter earnings call. We are pleased by the continued momentum in CASGEVY and expansion of access globally. To highlight, Vertex secured regulatory approvals in Bahrain, Kingdom of Saudi Arabia and the United Arab Emirates, and indicated that they also secured a reimbursement agreement with NHS England, resulting in access to CASGEVY in England for eligible sickle cell disease and beta thalassemia patients. Additionally, the cell and gene therapy access model was highlighted by Vertex as a mechanism for states to voluntarily participate in CMS negotiated agreements for Medicaid patients. We believe that this model has the potential to expand patient access to cell and gene therapies over time, which we view as a positive for patients, CASGEVY and future therapies enabled by MaxCyte. Our teams work diligently to provide regulatory, scientific and technical support to our customers as they progress through the clinic, and we have become increasingly excited by the potential for multiple therapies to come to market beginning next year and beyond. In 2027 and 2028, we see an opportunity for eight potential approved programs for lymphoma, leukemia, sickle cell disease, and genetic disease indication. As we approach 2029 to 2031, we believe there's potential for an additional 12 approved programs with indication expansion to solid tumors, multiple myeloma, and autoimmune diseases. In our fourth wave of potential approvals in 2030 and beyond, we see potential for approvals within neurodegenerative disease indications as well. The opportunity for approved therapies within our current SPL portfolio is vast and growing as we continue to add new SPL customers. In summary, we are pleased with our 2024 results, driven by the execution of our global sales team, our differentiated technology and customer support, and our process improvements across the organization. We increased our operational focus while making strategic investments in areas of high growth, resulting in a year-end cash position that exceeded our initial guidance. We look forward to continuing this momentum in 2025 and truly believe that our value proposition remains highly differentiated into durable relationships with current and prospective clients. Our investment strategy remains unchanged, in that we continue to focus on organic and inorganic investments that offer the best outcomes for our customers and MaxCyte, while preserving our healthy balance sheet. We are investing in the development of additional capabilities and products that our customers will need in the future, while simultaneously and carefully evaluating inorganic opportunities that we believe would benefit MaxCyte. We are committed to being diligent and disciplined in our approach to make decisions that position MaxCyte to become the premier comprehensive enabler of cell and gene therapies within the industry. With that, I will now turn the call over to Doug to discuss our financial results. Doug?

Thank you, Maher. Total revenue for the full year was 38.6 million, compared to 41.3 million in 2023, representing a 6% decline. Total revenue in the fourth quarter of 2024 was 8.7 million, compared to 15.7 million in the fourth quarter of 2023, representing a 45% decline. Total revenue declined due to multiple accrual milestones received and recognized in the fourth quarter of 2023. In the fourth quarter of 2024, we reported Core revenue of 8.6 million, compared to 7.2 million in the comparable prior year quarter, representing an increase of 20%. Within Core revenue, Instrument revenue was 1.6 million, compared to 2.3 million in the fourth quarter of 2023. License revenue was 2.6 million, compared to 2.4 million in the fourth quarter of 2023. And processing assembly, or PA revenue, was 4.2 million, compared to 2.2 million in the fourth quarter of 2023. As Maher discussed earlier, our instrument revenue was impacted by difficult operating environment in 2024, which led to customer caution around capital equipment purchasing. We were pleased with our strong PA revenue, along with stable revenue from licenses, which we believe demonstrates strength in our revenue from clinical stage SPL customers. For the full year of 2024, we reported Core revenue of 32.5 million, compared to 29.8 million in 2023, representing an increase of 9%. Within our Core revenue, Instrument revenue was 7.1 million, compared to 8.3 million in 2023. License revenue totaled 10.3 million, compared to 10.3 million in 2023. And PA revenue totaled 14 million, compared to 10.3 million in 2023. Of note, 55% of our Core business revenue was derived from SPL customers in 2024, which compares to 48% in 2023. We believe that the percentage of Core business revenue from SPLs remains at a healthy level. The year-over-year increase can be attributed to more customers entering the clinic and continued execution on signing new SPL agreements. We recognized 0.1 million of SPL program-related revenue in the fourth quarter of 2024, compared to 8.5 million in the fourth quarter of 2023. For the full year, we recognized 6.1 million in SPL program-related revenue, as compared to 11.5 million in 2023, well ahead of our initial guidance provided early last year. SPL program-related revenue includes a small amount of revenue from CASGEVY in the second half of the year. Before I continue down the P&L, I would like to point out that we will no longer be disclosing Core revenue by cell therapy and drug discovery, but rather focusing on instruments, licenses, PAs, and other revenue as the components of our Core revenue disclosure. Internally, we focus on these components of revenue across customers to forecast, track, and understand our business performance, and this updated level of disclosure is more closely aligned with how we think about the planning of our business. Moving down the P&L, gross margin was 74% in the fourth quarter of 2024, compared to 90% in the fourth quarter of the prior year, excluding inventory provisions and SPL program-related revenue, non-GAAP adjusted gross margin was 84% in the fourth quarter of 2024, compared to non-GAAP adjusted gross margin of 86% in the fourth quarter of 2023. Total operating expenses for the fourth quarter of 2024 were 19.3 million, compared to 22.2 million in the fourth quarter of 2023. The overall decrease in operating expenses was primarily driven by operational changes made in 2024. As Maher discussed, the company plans to continue to make targeted and disciplined investments to drive long-term growth, which include investments in new products and product enhancements for our customers, our commercial sales team, and investments to scale SeQure Dx. We ended 2024 with combined total cash and cash equivalents and investments of 190.3 million, and no debt. Moving to our initial 2025 guidance, we expect Core revenue growth of 8% to 15%, compared to 2024, inclusive of revenue from SeQure Dx, which we expect to be at least 2 million for the full year. We are not assuming a change in the current macroeconomic environment experienced by our customers within our guidance. We continue to remain in close discussions with our customers and how their needs might change throughout the year. MaxCyte navigated well through the continuation of a difficult operating environment in 2024, and we are very confident in our ability to commercially execute on our outlook for 2025. SPL program-related revenue is expected to be approximately 5 million in 2025, which includes both expected revenue from pre-commercial milestone payments and commercial royalties and sales-based payments. We will not break out the components of SPL program-related revenue due to confidentiality agreements with our customers. Additionally, we would like to note that our SPL program-related revenue outlook is a risk-adjusted forecast that is achievable under a variety of potential outcomes across our SPLs and planned clinical progress and commercial success of our customers. Finally, MaxCyte remains in a solid financial position and expects to end 2025 with approximately 160 million in cash, cash equivalents, and investments on our balance sheet. I'd like to close by stating that MaxCyte is well-positioned to deliver on our 2025 goals. We continue to remain dedicated to modest cash burn and operating as a streamlined organization to best support MaxCyte's long-term vision and growth outlook. Now I'll turn the call back over to Maher.

Thank you, Doug. We are proud of our progress thus far in 2025 and are in a great position to deliver high-quality support for our customers. I would like to thank our team at MaxCyte for their dedication to the company and our customers every day. With that, I will turn the call back over to the operator for the Q&A. Operator?

Certainly. And our first question for today comes from the line of Matt Larew from William Blair. Your question, please.

Hi. Good afternoon. Wanted to ask on the guidance for the Core business by backout SeQure Dx. Looks like something around 9% growth. Just maybe get a sense for what that reflects in terms of end market dynamics as well as where it is versus where you expect kind of a normalized or longer-term growth for the Core business to be?

Yes, Matt, nice to hear you again and good to talk. So let me take that for a second. I can turn over to Doug as needed as well. We're still seeing continued growth across our customer base, both on the research side as well as the technical side. As we saw throughout 2024, we saw increased PA usage as well, which is a very good sign that we talked about when we see that market recovery. A lot of it has to do with the fact that we continue to believe the operational changes that we've made, and the execution that we believe we can continue to make throughout the year should give us a year-over-year growth similar to what we had in 2024 versus 2023. It's across the board, Matt. It's not one particular area. It's the execution of the commercial team, scientific team, and organization as a whole to understand where the market's going and have those precise call points that we were able to take on in 2024 and continue in 2025. Doug, anything else to add there?

Hi, Matt. Instruments did decline in 2024 versus 2023. We see opportunities to start pulling that in the right direction. PA sales were strong last year versus 2023, and so we expect or hope that will continue. That's built into our forecast, looking at a run rate that is aligned with the rolling experience on a pull-through basis and looking at our forecast for instruments. So as Maher mentioned, it's across the board. We expect to see some growth this year, but we're being a little bit conservative in the guidance.

Okay, understood. And then on SeQure Dx, you mentioned $2 million included this year. Do you think it gives a sense for sort of what the revenue track record is there, how much they have been growing, expanding customers? If there's any business model changes or bundling you're anticipating doing, I think that could be helpful in terms of framing how that's going to fit in and scale up throughout the year?

Great question. SeQure Dx began commercializing in 2024 as their first full year of commercialization, so it's very early in the process. We see great growth for SeQure Dx, but we're being fairly modest in our growth projections for them in 2025 as well. Obviously, this is greater revenue this year than they had in 2024, and we feel that we can continue to grow that. The business model is a services-based model with a highly differentiated service that truly only they can do. There's not much competition that can meet their service capabilities and the soft IP they're building around their assays, whether it's their GUIDE-seq assays or ONE-seq assays or their screening assays. The business model really fits into what we do, which is highly scientific and differentiated, where we can work with developers to ensure their timeline to the clinic is faster in a safer, more consistent manner. That's what SeQure Dx does. In essence, it's an extension of what MaxCyte has built our company around, and we feel confident in the at least $2 million expectation. We expect to grow it at a fairly fast rate based on their current infrastructure and integrating them into our commercial team as well. Doug?

I just want to reiterate a point from the press release and our comments. Core revenue is expected to grow 8% to 15%, inclusive of revenue from SeQure Dx, and we expect SeQure Dx to be at least $2 million. We're not breaking out specific line-item contributions at this point in the year, but we'll start to provide more detail when we report in May.

Okay. Thank you.

Thank you. And our next question comes from the line of Julie Simmonds from Panmure Liberum. Your question, please.

Hi. Yes. Just on SeQure again, I was just wondering how much in the way of costs are going to integrate into sort of MaxCyte as a whole, because I'm guessing in terms of sort of some of the basic infrastructure, you can take out some of the costs involved with that business fairly swiftly?

That's right, Julie. The incremental cost to our continuing operating expenses is fairly immaterial. We have the entire commercial infrastructure to support them. It is immaterial cost and it is included in our guidance in terms of what our end-of-year cash includes for SeQure Dx operating expenses. We feel very confident that the addition of SeQure Dx can leverage what we've built here over the past few years, especially since our IPO, where the team we've built can commercialize SeQure Dx's assays with very immaterial operating expenses attributable to SeQure Dx.

There is a cost structure associated with operating that line of business. There's a facility in Waltham and we'll be continuing to make some investments there, but it's not going to be a material part of our burn. We feel optimistic that the business can contribute on a cash flow basis in relatively short order. One of the things we like is that our investments are extremely scalable, and we look forward to seeing growth hit the bottom line as conditions improve for our end users and we continue to execute our plan. The leverageability of our cost structure is significant.

Excellent. Thank you. And just another one on sort of your exposure to the academic markets and NIH spending, because I know that has been an area where you've sold a reasonable amount of instrumentation in the past. I was just wondering whether you've noticed any change in that environment at the moment?

Actually, it has been a somewhat insignificant part of our business in terms of where we can directly link it to a grant. So we don't think this is going to have a material impact in the short term. We want to see continued robust investment in cell and gene therapy, including on the front end. Long term it could be challenging, but I don't expect an impact in the short term.

Yes. The exposure to NIH grants is very, very minimal. We're talking about roughly $200,000; it's immaterial. Our focus has been on biotech companies and later-stage companies getting ready for the clinic. So the exposure to NIH is immaterial at best.

Excellent. That's very good news. And then just as far as the SPL environment is concerned, are you still seeing customers wanting to sign off at the similar sort of stage and that most of them are at the pre-IND level or are they looking at any earlier stage when they sign those agreements?

No, that's a great question, Julie. It's still at that pre-IND level. As I mentioned on a previous call, we work with these customers oftentimes for a year before they engage, showing our differentiated technology and scientific support. When they're close to that pre-IND, that's when they begin negotiations with us. We're confident we can guide to three to five SPLs a year. It's a sign of the health of our business and our differentiated platform. The timing remains consistent.

Brilliant. Thank you very much.

We're on track. We've got one in the books and we're off to a good start in the first quarter.

That's right.

Thank you. And our next question comes from the line of Brendan Smith from TD Cowen. Your question, please.

Great. Thanks for taking the questions. Congrats on the progress, guys. Appreciate the color on the thinking that went into 2025 guidance. So maybe just kind of one more with respect to the SeQure integration. Can you just kind of maybe remind us a bit how we should think about kind of the combined company gross margins? Where you think those could go over the near and maybe a little bit longer term as that kind of gets ramped up there? And then any potential or even maybe likelier opportunities for upside to top line numbers that you would maybe call out for 2025? I know you're not necessarily baking in huge recovery just into the guidance itself. And then maybe I'll just have a follow up after that. Thanks.

If I hear your question correctly, you're asking first about how SeQure integration can contribute to our margins and secondly about upside to the top line for 2025. Is that right?

So I think for SeQure, really just how we should think about kind of the combined gross margins there. And then separately, any potential opportunities for upside that you guys would want to call out for this year specifically, independent of that?

Doug, how do you weigh the combined gross margins?

Without getting too granular, we have healthy gross margins and we look at them on an adjusted basis. We take out SPL revenue, which comes in without costs associated with it, and we've adjusted for any inventory provisions. We expect to continue to enjoy high margins in the low to mid-80s, even with SeQure integrated.

To your question on the combined margins, part of why SeQure made sense is their healthy gross margins. We feel confident that combined gross margins will remain in the low to mid-80s in the foreseeable future. Regarding top-line upside beyond our 8% to 15% guidance, we took a somewhat conservative stance. We're not assuming market improvement, so if the operating environment improves, there's upside beyond the current range. The range is intended to reflect both potential market conditions and our execution.

We're not really baking in any improvement or further deterioration. The range reflects both the health of the operating environment and our ability to execute. If the market recovers, there could be additional upside beyond the range.

Okay. Great. Thanks, guys. Very helpful.

Yes. Thanks, Brendan.

Thank you. And our next question comes from a line of Mark Massaro from BTIG. Your question, please.

Hi, guys. Thanks for taking the questions. So, I think the SeQure acquisition is pretty interesting in the sense that it broadens out your pipeline. I think beyond - you talked about both ex vivo and in vivo, as well as viral and non-viral. Is there any way that you could share what, I think you talked about 201 cell and gene companies with 83, I think that may be opportunities for you. Can you just give us a sense of the overlap of customers between SeQure and MaxCyte prior and what the incremental opportunities are leveraging SeQure product offerings?

Great question. The opportunity is enormous. SeQure provides assessments for both viral and non-viral programs. We have 84 non-viral programs that MaxCyte's transfection platform can target; SeQure can also target those. But SeQure also can target the broader clinical landscape. When you look at the full picture, there are hundreds of programs across pre-clinical and clinical stages that SeQure can address. This expands our footprint across the entire cell and gene therapy space, both ex vivo and in vivo, viral and non-viral. So there's overlap with our existing programs, and SeQure gives us the ability to extend into many more programs across the broader landscape.

That's very helpful. And then can you perhaps go into a little more detail about SeQure revenue opportunity? I guess what I'm really asking is, how do they monetize? I know it's a services company. So, is this like a fee-for-service or is this I'm just curious how the revenue gets recognized, if it's like a subscription, trying to figure out how lumpy it is as we think about going out a couple years?

Right now, it's a fee-for-service model with the opportunity to explore subscription-based models for certain assay services as we scale and depending on the stage of development. Today, it's primarily fee-for-service with highly differentiated assays and the potential for other commercial structures as we expand.

Okay. And I think I heard you guys, but just checking that the guidance for 2025 does not assume any change to the environment. And I think the environment is broad, but I just want to make sure you're assuming capital raising environment, macro environment, basically all potential risk factors at this time?

We're providing a range for revenue made up of various components. We think SeQure has significant growth opportunities. In terms of this year, we're not counting on a recovery or the market changing significantly. The range covers shades of the current environment. If things improve materially or deteriorate, those outcomes could fall outside the range. The range is a combination of operating environment expectations and our ability to execute against opportunities. If the market recovers, that could provide upside.

Sounds good. I will hop back in the queue.

Thank you, Mark.

Thank you. Our next question comes from the line of Dan Arias from Stifel. Your question please.

Thanks for the question. This is Paul on for Dan. I guess just touching on the guide for core revenue, you talked about not baking in any improvement throughout the year, even though there is some upside there. As you said, you're cautiously optimistic that there will be a better funding environment, but just in terms of not baking that in, how does that play into what the quarterly cadence is going to be from a guidance perspective? Can you just give us some color there?

Just to reiterate, the components of revenue include SeQure and Core revenue elements. We don't expect lumpiness from SeQure. License revenue is relatively stable and can be modeled evenly across the year. For processing assemblies, we model from a rolling installed base pull-through rate. We don't expect significant lumpiness, though historically the third quarter can be weaker than the fourth. Historically, the lumpy component tends to be instruments, which are tied to identified opportunities and conversion rates. If there is lumpiness, it's most likely in instrument sales.

Okay. That's helpful. And then just the one follow-up is you talked about the conservatism in the guide for SeQure. And I think when the acquisition came out, you had said that the business transitioned over towards the service revenue in March of 2024. Can you kind of touch on to what extent the growth this year is just kind of lapping that transition and getting that higher service revenue in the first quarter versus integration into your overall commercial infrastructure versus just kind of expansion of the business and penetrating more customer accounts?

I think it's important to realize just how early that business is from the point of when they came out of stealth and were actually operating the business. That early-stage progression is part of the story.

Great question, Paul. The $2 million-plus expectation is based on the expansion of the services SeQure rolled out in 2024 and integration into MaxCyte's commercial team. As we more fully integrate SeQure Dx into our commercial infrastructure through the year, we expect to expand their reach and grow the services business beyond what they achieved in 2024.

Great. Thanks for the answers. I'll jump back in the queue.

Thank you. And our next question comes from the line of Matt Hewitt from Craig-Hallum. Your question, please.

Good afternoon. Thanks for taking the questions. Maybe first up on SeQure, is the sales and marketing effort, has that been integrated yet or when do you anticipate that could occur?

It has been integrated from day one upon the acquisition a little over a month ago. The marketing and sales integration has happened from day one. Over the course of the year we'll continue marketing efforts, ensure conference presence and application notes that highlight their differentiated assays, but the integration has already occurred.

Got it. And then maybe just kind of taking a step back on the macro, as you've had conversations over the past three to four months, have you noticed or heard any change in the conversations that you're having with customers? There's been a lot of noise over the past couple of weeks, tariffs, budget cuts, all that kind of stuff. What are you hearing from customers? Has that changed at all or are they still feeling like it's steady as it goes and progressing?

Fifty-five percent of our revenue is from SPL customers, and programs are progressing through the clinic in ordinary course. Outside of that, opinions vary. At this point in the year, we're comfortable with the guidance we're providing based on current conditions, even with some additional headwinds.

Last year we saw some deprioritization of programs, but that has leveled off and stabilized. We saw a trough through last year that's now stabilized, and that stabilization has continued through the first quarter. What we're seeing now is execution in the current market and another year of returning to growth as we did in 2024.

That's great. Thank you very much.

Absolutely. Thank you, Matt.

Thank you. And this does conclude the question-and-answer session of today's program. I'd like to hand the program back to Maher for any further remarks.

Thank you, operator. And thank you, everyone, for joining us on today's call. We look forward to speaking to you again on our next earnings call in a few months. Thank you.

Thank you, ladies and gentlemen, for your participation in today's conference. This does conclude the program. You may now disconnect. Good day.